Biotech · Private company
Healx Limited
Track this companyFree. Adds Healx Limited to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Gaboxadol (HLX-0206)Phase 2 · Fragile X SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- HLX-1502Phase 2 · Neurofibromatosis Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Sulindac (HLX-0201), dose strength 1Phase 2 · Fragile X SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Sulindac (HLX-0201), dose strength 2Phase 2 · Fragile X SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1PHASE2 · RECRUITING · started Feb 10, 2025ClinicalTrials.gov NCT06541847 · fetched Nov 12, 2026
- Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)PHASE2 · COMPLETED · started Jan 29, 2024ClinicalTrials.gov NCT06334419 · fetched Nov 12, 2026
- Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40PHASE2 · WITHDRAWN · started May 25, 2022ClinicalTrials.gov NCT04823052 · fetched Nov 12, 2026